NEW YORK (GenomeWeb News) — MDS today reported that first-quarter revenue for its Sciex division increased 1.5 percent, though organic receipts increased 4 percent.
Total revenue for the three months ended Dec. 31, 2006, increased to $62 million from $61 million.
Driving revenue were the small molecule and applied markets and in Europe, MDS said.
MDS also said end-user revenue in the company’s joint ventures increased 10 percent.
R&D spending remained flat at $4 million.
The company did not break out earnings or a balance sheet for the unit.